RNAi Technology is Estimated to Witness High Growth Owing to Advancements in Target Identification and Delivery Systems

 

RNAi Technology Market Demand 

RNA interference (RNAi) technology is a biological process where RNA molecules inhibit gene expression or translation. This promises potential application for treating various diseases and has emerged as a promising drug development tool. RNAi helps in silencing specific genes responsible for disease pathogenesis. It functions by cleaving mRNA molecules and inhibiting production of target proteins. This targeted gene silencing through RNAi offers advantages over traditional medicines as it allows modulating expression of almost any human gene. The Global RNAi Technology Market is estimated to be valued at US$ 2490.58 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the RNAi Technology are F. HOFFMANN-LA ROCHE AG, PFIZER, INC., ASTELLAS PHARMA INC., NOVARTIS INTERNATIONAL AG, ASTRAZENECA PLC, BRISTOL-MYERS SQUIBB COMPANY, ABBVIE INC., AMGEN, INC., MERCK & CO., INC., JOHNSON & JOHNSON.

The key opportunities in the market include increasing research activity on target identification and validation. Several RNAi Technology Market Demand technologies are being explored for treating cardiovascular diseases, viral infections, neurodegenerative disorders and cancer.

Significant advancements have been made in the delivery systems for RNAi therapeutics. Novel delivery vectors such as lipid nanoparticles, exosomes, and fusogenic liposomes have improved targeting efficiency and biodistribution of RNAi drugs. Advent of customized endogenous RNAi triggers platforms is also opening avenues towards tissue or disease specific targeting.

Market Drivers

The major market driver is growing demand for therapies addressing previously undruggable gene targets. RNAi therapy allows targeting a wide range of genes that were earlier not considered druggable. Large unmet clinical needs, Minimal toxicity and side effects of RNAi drugs as compared to small molecule inhibitors or monoclonal antibodies is fueling the market growth.

Current challenges in RNAi Technology Market:

- Delivery remains a major challenge as RNA molecules cannot enter the cells on their own due to their negatively charged backbone. Improving the delivery efficiencies of RNAi components like siRNA and miRNA is still an active area of research.

- Non-specific immunity activation by RNAi components is another limitation as components are seen as foreign by the immune system. This leads to reduced efficacy and stability of RNAi components in vivo.

- Lack of cell specificity results in off-target effects in non-relevant tissues and cell types. Improving tissue and cell targeting remains an important challenge.

- High production costs associated with GMP grade production of RNAi therapeutic components limits wide availability. Scaling up production needs addressing.

SWOT Analysis

Strength: High potential for treatment of previously undruggable genetic diseases. RNAi offers sequence-specific gene silencing not seen with small molecule drugs. Weakness: Delivery challenges have slowed clinical progress. Manufacturing complexities and costs are also limitations. Opportunity: Expanding pipeline into oncology and metabolic diseases indications. Better delivery technologies can help overcome current barriers. Threats: Slow regulatory approvals and technical hurdles prolong time to market impacting returns on investment. Intense competition from other novel modalities requires continued innovation.

Geographical regions with market concentration:

North America currently captures over 35% of the global RNAi technology market value due to availability of advanced healthcare facilities and presence of major players. Presence of high R&D spending and adoption of novel therapies also contribute to its large share.

Fastest growing region:

The Asia Pacific region is poised to exhibit highest growth during the forecast period owing to rising healthcare expenditures, large patient pools, and growing focus of international players on establishing manufacturing and research centers in countries like China and India. Governments also support local biotech industries through funding and initiatives to develop RNAi as an indigenous technology.

Get More Insights on- RNAi Technology Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)